Chemotherapy plus immunotherapy vs. immunotherapy alone for older adults with lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study compares getting both chemotherapy and immunotherapy versus immunotherapy alone for older adults with advanced lung cancer. The goal is to see which approach is more effective and tolerable for people aged 70 and older.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years old or older.
- Your lung cancer is stage IIIB, IIIC, or IV (it has spread) and you are not able to have combined chemo-radiation.
- Your cancer has a PD-L1 level between 1 and 49%.
- You have not had chemotherapy or immunotherapy for cancer that has spread before. (Earlier treatment is allowed.)
- You are generally able to do daily activities, even if you need some rest (ECOG 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and immunotherapy for people 65 or older with metastatic non-small cell lung cancer that has not been treated before and expresses PD-L1. It aims to see if this treatment can help control the cancer.
This study tests a milder chemotherapy combined with an immunotherapy drug (anti-PD-1) as the first treatment for advanced lung cancer in older or frailer adults. It aims to see if this approach works better with fewer side effects.
This trial is testing a combination of an oral chemotherapy pill (vinorelbine) and an immunotherapy drug (PD-1 inhibitor) for people aged 65 and older with advanced non-small cell lung cancer who have not had treatment before. The goal is to see if this approach can help control the cancer with fewer side effects.
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
This trial tests whether a reduced dose of chemotherapy plus an immunotherapy drug (Cemiplimab) works better than Cemiplimab alone for older or frail patients with advanced lung cancer whose PD-L1 level is below 50%. It aims to find a gentler but effective treatment option.
This trial tests a new way to treat non-small cell lung cancer in people aged 70 or older. You will receive oral chemotherapy (paclitaxel) with immunotherapy and focused radiation (SBRT) before surgery, hoping to shrink the tumor and improve outcomes.
Hear when a new Advanced Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.